| [1] |
MOULARD O,MEHTA J,FRYZEK J,et al.Epidemiology of myelofibrosis,essential thrombocythemia,and polycythemia vera in the European Union[J]. Eur J Haematol,2014,92(4):289-297.
|
| [2] |
SROUR S A,DEVESA S S,MORTON L M,et al.Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States,2001-12[J]. Br J Haematol,2016,174(3):382-396.
|
| [3] |
STEVEN H,CAMPOE,HARRISNL,et al.WHO classification of tumors of haematopoietic and lymphoid tissues[M]. Lyon:IARC Press,2017:21-22.
|
| [4] |
MICHIELS J J,TEVET M,TRIFA A,et al.2016 WHO clinical molecular and pathological criteria for classification and staging of myeloproliferative neoplasms(MPN) caused by MPN driver mutations in the JAK2,MPL and CALR genes in the context of new 2016 WHO classification:prognostic and therapeutic implications[J]. Maedica(Buchar),2016,11(1):5-25.
|
| [5] |
SHIM H,HA J H,LEE H,et al.Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma[J]. Biomed Res Int,2014,2014:893243.
|
| [6] |
JEN E Y,KO C W,LEE J E,et al.FDA approval:gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia[J]. Clin Cancer Res,2018,24(14):3242-3246.
|
| [7] |
JILANI I,ESTEY E,HUH Y,et al.Differences in CD33 intensity between various myeloid neoplasms[J]. Am J Clin Pathol,2002,118(4):560-566.
|
| [8] |
RUMI E,CAZZOLA M.Diagnosis,risk stratification,and response evaluation in classical myeloproliferative neoplasms[J]. Blood,2017,129(6):680-692.
|
| [9] |
LUNDBERG P,KAROW A,NIENHOLD R,et al.Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms[J]. Blood,2014,123(14):2220-2228.
|
| [10] |
ORTMANN C A,KENT D G,NANGALIA J,et al.Effect of mutation order on myeloproliferative neoplasms[J]. N Engl J Med,2015,372(7):601-612.
|
| [11] |
PIETRA D,RUMI E,FERRETTI V V,et al.Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms[J]. Leukemia,2016,30(2):431-438.
|
| [12] |
SANGLE N,COOK J,PERKINS S,et al.Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically,biologically,and prognostically indistinguishable from primary myelofibrosis[J]. Appl Immunohistochem Mol Morphol,2014,22(9):663-668.
|
| [13] |
RUMI E,PIETRA D,FERRETTI V,et al.JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes[J]. Blood,2014,123(10):1544-1551.
|
| [14] |
KUSSICK S J,WOOD B L.Four-color flow cytometry identifies virtually all cytogenetically abnormal bone marrow samples in the workup of non-CML myeloproliferative disorders[J]. Am J Clin Pathol,2003,120(6):854-865.
|
| [15] |
DE PROPRIS M S,RAPONI S,DIVERIO D,et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation[J]. Haematologica,2011,96(10):1548-1551.
|
| [16] |
OUYANG J,ZHENG W,SHEN Q,et al.Flow cytometry immunophenotypic analysis of philadelphia-negative myeloproliferative neoplasms:correlation with histopathologic features[J]. Cytometry B Clin Cytom,2015,88(4):236-243.
|
| [17] |
AGIS H,KRAUTH M T,MOSBERGER I,et al.Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7[J]. J Clin Pathol,2006,59(4):396-402.
|
| [18] |
FENG B,VERSTOVSEK S,JORGENSEN J L,et al.Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis[J]. Am J Clin Pathol,2010,133(2):314-320.
|
)
